We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Synlogic Inc | NASDAQ:SYBX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | -2.13% | 1.84 | 1.78 | 7.25 | 1.90 | 1.81 | 1.89 | 29,923 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Shares of Synlogic Inc. fell more than 25% in premarket trading Thursday after the biopharmaceutical company said its collaboration with AbbVie Inc. had ended.
Synlogic and AbbVie in late 2015 agreed to develop medicines for the potential treatment of inflammatory bowel disease using Synlogic's Synthetic Biotic platform.
The deal included an upfront payment of $2 million to Synlogic, along with up to $16.5 million in milestone payments.
Synlogic said that with the termination of the AbbVie collaboration, it regains all rights to develop Synthetic Biotic medicines for inflammatory bowel disease, as well as the rights to form new partnerships.
Shares of Synlogic, which closed Wednesday at $2.43, were down 25.5% to $1.81 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 21, 2020 08:28 ET (12:28 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Synlogic Chart |
1 Month Synlogic Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
